CASI Pharmaceuticals Company Description
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People’s Republic of China, the United States, and internationally.
It offers EVOMELA, a Melphalan injection for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma.
The company also develops CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with hematological malignancies; BI-1206, an novel anti-FcγRIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody for the treatment of patients with multiple myeloma; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants.
It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C.
to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 1991 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 214 |
| CEO | Wei-Wu He |
Contact Details
Address: 1701-1702, China Central Office Tower 1 Beijing, 100025 China | |
| Phone | 86 10 6508 6063 |
| Website | casipharmaceuticals.com |
Stock Details
| Ticker Symbol | CASIF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | KYG1933S1012 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wei-Wu He Ph.D. | Executive Chairman of the Board and Principal Executive Officer |
| Kun Qian | Vice President and Global Controller |
| Chunhua Wang | Chief Operating Officer |
| Wei Gao | General Counsel |
| Dr. Wei Zhang Ph.D. | Senior Vice President |
| Hai Huang | Chief Commercial Officer and GM |
| Dr. James E. Goldschmidt Ph.D. | Chief Business Officer |
| Dr. Junping Chen M.D., Ph.D. | Senior Vice President of Medical of US and Chief Medical Officer of China |